These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38253480)

  • 1. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    He T; Zhang D
    Gut; 2024 Oct; 73(11):e28. PubMed ID: 38253480
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of Patients with HBeAg-Positive.
    Choi WM; Lim YS
    Hepatology; 2024 Aug; 80(2):E28. PubMed ID: 38607785
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
    Luo C
    Hepatology; 2024 Oct; 80(4):E57. PubMed ID: 38743007
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk-A multinational cohort study of HBeAg-positive patients.
    He T; Zhang D
    Hepatology; 2024 Aug; 80(2):E26-E27. PubMed ID: 38607724
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
    Liao X; Fan R
    Hepatology; 2024 Sep; 80(3):E46-E47. PubMed ID: 38919029
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors.
    Cunha-Silva M; Marinho FRT; Oliveira PF; Lopes TM; Sevá-Pereira T; Lorena SLS; Almeida JRS
    Braz J Infect Dis; 2017; 21(4):441-447. PubMed ID: 28554002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?
    Howell J; Chan HLY; Feld JJ; Hellard ME; Thompson AJ
    Gastroenterology; 2020 Jun; 158(8):2028-2032. PubMed ID: 32088205
    [No Abstract]   [Full Text] [Related]  

  • 8. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
    Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
    World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.
    Wei Q; Xu X; Ling Q; Zhou B; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):251-5. PubMed ID: 23742769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of hepatitis B virus-related hepatocellular carcinoma.
    Ishikawa T
    World J Gastroenterol; 2010 May; 16(20):2463-7. PubMed ID: 20503445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.
    Choi WM; Yip TC; Kim WR; Yee LJ; Brooks-Rooney C; Curteis T; Clark LJ; Jafry Z; Chen CH; Chen CY; Huang YH; Jin YJ; Jun DW; Kim JW; Park NH; Peng CY; Shin HP; Shin JW; Yang YH; Wong GL; Lim YS
    Hepatology; 2024 Aug; 80(2):428-439. PubMed ID: 38436992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma.
    Gong WF; Zhong JH; Lu SD; Wang XB; Zhang QM; Ma L; Zhang ZM; Xiang BD; Li LQ
    Oncotarget; 2017 Feb; 8(9):15047-15056. PubMed ID: 28122361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stemming the tide of hepatitis B virus related hepatocellular carcinoma?
    Thomas MB; Davila M; Abbruzzese JL
    J Clin Oncol; 2008 Jan; 26(2):172-4. PubMed ID: 18182657
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
    Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.
    Seo Y; Yano Y
    World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
    Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
    J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic viruses and hepatocellular carcinoma.
    Ben Ari Z; Weitzman E; Safran M
    Clin Liver Dis; 2015 May; 19(2):341-60. PubMed ID: 25921667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence.
    Hoshida Y
    J Hepatol; 2009 Nov; 51(5):842-4. PubMed ID: 19748698
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical implications of hepatitis B virus genotype: Recent advances.
    Lin CL; Kao JH
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():123-30. PubMed ID: 21199523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.